Loading clinical trials...
Loading clinical trials...
Phase 2a Prospective, Randomized, Double-blind, Intra-subject, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy of OLX10010 as an Adjunct Therapy to Reduce the Recurrence of Hypertrophic Scars After Scar Revision Surgery
Conditions
Interventions
OLX10010
Locations
6
United States
MedStar Health Research Institute
Washington D.C., District of Columbia, United States
Miami Dermatology & Laser Research, LLC
Miami, Florida, United States
Miami Plastic Surgery
Miami, Florida, United States
Henry Ford Health System
Detroit, Michigan, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Paddington Testing Co, Inc.
Philadelphia, Pennsylvania, United States
Start Date
August 19, 2021
Primary Completion Date
January 11, 2023
Completion Date
July 12, 2023
Last Updated
February 21, 2024
NCT07336368
NCT07147166
NCT03561376
NCT06487910
NCT04506255
NCT06104540
Lead Sponsor
Olix Pharmaceuticals, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions